• Antibiotic Use and Resistance in Psychiatric Hospitals

  2026-10-05

  This retrospective study examined antibacterial use and resistance patterns in a psychiatric hospital during the 2022 epidemic, combining hospital utilization metrics with microbiological surveillance. Its main contribution is a setting-specific view showing relatively low antibiotic use alongside substantial resistance concerns, supporting continued, data-driven stewardship rather than simple reliance on aggregate prescribing rates.

• SFRP1, Wnt Signaling, and Oral Submucous Fibrosis

  2026-10-03

  A 2024 mouse and cell study links reduced SFRP1 with neutrophil infiltration, fibrosis, and increased Wnt/β-catenin signaling in arecoline-induced oral submucous fibrosis. The findings support a mechanistic model in which SFRP1 may restrain inflammatory recruitment and fibrotic signaling, while also highlighting the limits of translating preclinical pathway observations into clinical treatment.

• Necrostatin-1 Workflows for RIP1 Kinase Research

  2026-10-02

  Build more interpretable necroptosis assays with Necrostatin-1, a selective RIP1 kinase inhibitor for pathway validation, inflammatory injury models, and host–pathogen experiments. This guide connects practical cell-based workflows with the cross-strain CRISPR findings of a Toxoplasma gondii virulence study.

• From Lactylation to Viability in ccRCC

  2026-10-01

  A translational framework for using Cell Counting Kit-8 (CCK-8) Plus to connect the AARS2–ULK1 lactylation axis with scalable viability, proliferation, cytotoxicity, and drug-response studies in clear cell renal cell carcinoma.

• Cyanidin Chloride for Oxidative Stress Assays

  2026-10-01

  Cyanidin Chloride supports integrated oxidative stress research that connects reactive oxygen species scavenging with inflammatory signaling and epithelial-barrier readouts. This workflow-focused guide shows how to handle the compound, build a defensible cell assay, and interpret evidence without conflating cyanidin chloride with the glycoside studied in a psoriasis model.

• Chloroquine Diphosphate: From Flux to Translation

  2026-09-30

  A mechanistic and translational guide to using Chloroquine Diphosphate as an autophagy perturbation tool, while separating lysosomal flux effects from cell-cycle arrest, innate immune signaling, and combination-treatment responses.

• Propidium Iodide: Reading Cell Death Precisely

  2026-09-30

  Propidium iodide is more than a red DNA stain: its signal reports both membrane access and nucleic-acid content. This guide develops a decision framework for cell viability assay, apoptosis detection, and cell-cycle analysis, with practical insight from an ATR–ALT cancer study.

• Network Medicine Identifies Apigenin for Alzheimer’s

  2026-09-29

  A 2025 study used network proximity to prioritize flavonoids with potential relevance to Alzheimer’s disease and identified Apigenin as the strongest candidate among four compounds tested in cell models. The work connects computational target prioritization with mitochondrial protection, apoptosis suppression, AKT/NF-κB modulation, and microglial phenotype regulation, while leaving brain exposure and in vivo efficacy unresolved.

• G-Quadruplexes, TDP-43 Condensation, and Toxicity

  2026-09-29

  Oldani et al. show that RNA G-quadruplexes directly influence TDP-43 aggregation, stress-associated condensation, cellular distribution, and toxicity across biochemical and cellular models. The findings position G-quadruplex population and stability as experimentally testable regulators of TDP-43 proteostasis, while also highlighting the need to distinguish structure-specific effects from general consequences of nucleic-acid binding or stress.

• GSK-923295 for CENP-E Mitosis Assays

  2026-09-28

  GSK-923295 provides a pharmacological way to interrogate CENP-E-dependent chromosome congression, mitotic arrest, and tumor-cell vulnerability. Combined with the reference study’s CTCF-degron strategy, it helps distinguish motor inhibition from broader centromere-architecture defects in cancer research assays.

• Pifithrin-α: Testing p53-Driven Ferroptosis

  2026-09-28

  Pifithrin-α is a p53 inhibitor that can help test whether p53 contributes to ferroptosis-associated neuronal injury. This guide uses a maternal deltamethrin study to show how to design stronger causal experiments—and where pharmacological inhibition alone is not enough.

• MK-5108 (VX-689) for Aurora A Research

  2026-09-27

  Use MK-5108 (VX-689) to test whether Aurora A activity contributes to cell-cycle disruption and tumor-cell growth, with a workflow that connects target engagement to functional readouts. A 2024 retinoblastoma study strengthens the rationale for examining AURKA, while careful controls are needed before extending its findings to this inhibitor or disease model.

• Vitamin C, Organoids, and Translational Rigor

  2026-09-26

  Vitamin C research spans dose-dependent cancer-cell findings and emerging organoid models of infection—but those evidence streams are not interchangeable. This article outlines what the data support, where the gaps remain, and how translational teams can design more interpretable experiments with ascorbic acid.

• 25HC Reprograms Tumor-Associated Macrophages

  2026-09-25

  Xiao et al. identify a CH25H–25-hydroxycholesterol pathway that links lysosomal sensing to AMPKα activation and STAT6-dependent immunosuppressive programming in tumor-associated macrophages. The study positions CH25H as a candidate immunometabolic checkpoint and reports that disrupting it can improve antitumor responses, including responses to anti-PD-1 in experimental models.

• Tamoxifen Workflows: Precision, Controls, and Safety

  2026-09-25

  Tamoxifen supports both CreER-based genetic studies and estrogen-receptor-focused cancer research, but its effects depend on dose, timing, tissue, and model. A mouse developmental study shows why induction conditions and tamoxifen-only controls matter as much as recombination efficiency.

7110 records 1/474 page Next 12345 下5页 Last page